泌尿外科远程医疗:系统综述及COVID-19疫情期间与之后的应用价值
该系统综述检索PubMed和Scopus数据库,纳入45项研究(含12项随机对照试验),评估远程医疗在泌尿外科的应用。文献表明远程医疗在前列腺癌决策与随访、血尿初诊、无并发症结石和尿路感染管理、尿失禁行为治疗与盆底肌训练等场景可成功实施,但长期疗效、安全性和卫生经济学数据仍需加强。
要点
- 远程医疗可用于非转移性前列腺癌决策、局限性前列腺癌治愈后随访。
- 无并发症尿路结石和尿路感染的管理与随访适合远程医疗。
- 尿失禁初始评估、行为治疗和盆底肌训练可远程实施。
核心结论
- 远程医疗在前列腺癌、尿失禁、盆腔器官脱垂、无并发症尿路结石和尿路感染等选定患者中已成功实施。
- 许多泌尿外科疾病适合远程医疗,但其他高发恶性与良性疾病仍需更多研究。
- COVID-19疫情可能显著推动远程医疗的应用,但长期疗效、安全性和卫生经济学仍需更可靠数据。
研究设计与样本
- 系统综述,已在PROSPERO注册,检索PubMed和Scopus数据库,收集评估任何泌尿外科疾病中远程医疗干预的任何类型研究。
- 共纳入45项研究,包括12项随机对照试验;使用NTP/OHAT偏倚风险评级工具评估偏倚风险,采用叙述性综合。
主要发现
- 45项研究中,前列腺癌11项、血尿管理3项、尿路结石6项、尿失禁14项、尿路感染5项、其他疾病6项。
- 远程医疗在非转移性前列腺癌诊断后决策、局限性前列腺癌治愈后随访、血尿初诊等场景成功实施。
- 远程医疗还用于无并发症尿路结石和尿路感染的管理诊断与随访,以及尿失禁初始评估、行为治疗和盆底肌训练。
- 远程医疗也用于压力性尿失禁或盆腔器官脱垂手术后的随访。
- 大多数报告的方法学质量良好。
临床怎么用
- 对选定患者的前列腺癌决策与随访、无并发症结石和尿路感染、尿失禁行为治疗与盆底肌训练,可考虑采用远程医疗。
- 血尿初诊和盆腔器官脱垂术后随访也可在适当条件下通过远程医疗进行。
- 应用远程医疗时应关注长期疗效、安全性和卫生经济学证据的不足。
局限性
- 泌尿外科远程医疗文献稀疏。
- 其他高发泌尿外科恶性与良性疾病的研究不足。
- 长期疗效、安全性和卫生经济学数据仍需更可靠研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Coronavirus disease 2019 (COVID-19) pandemic has caused increased interest in the application of telehealth to provide care without exposing patients and physicians to the risk of contagion. The urological literature on the topic is sparse. OBJECTIVE: To perform a systematic review of the literature and evaluate all the available studies on urological applications of telehealth. EVIDENCE ACQUISITION: After registration on PROSPERO, we searched PubMed and Scopus databases to collect any kind of studies evaluating any telehealth interventions in any urological conditions. The National Toxicology Program/Office of Health Assessment and Translation Risk of Bias Rating Tool for Human and Animal Studies was used to estimate the risk of bias. A narrative synthesis was performed. EVIDENCE SYNTHESIS: We identified 45 studies (11 concerning prostate cancer [PCa], three hematuria management, six urinary stones, 14 urinary incontinence [UI], five urinary tract infections [UTIs], and six other conditions), including 12 randomized controlled trials. The available literature indicates that telemedicine has been implemented successfully in several common clinical scenarios, including the decision-making process following a diagnosis of nonmetastatic PCa, follow-up care of patients with localized PCa after curative treatments, initial diagnosis of hematuria, management diagnosis and follow-up care of uncomplicated urinary stones and uncomplicated UTIs, and initial evaluation, behavioral therapies, and pelvic floor muscle training in UI patients, as well as follow-up care after surgical treatments of stress urinary incontinence or pelvic organ prolapse. The methodological quality of most of the reports was good. CONCLUSIONS: Telehealth has been implemented successfully in selected patients with PCa, UI, pelvic organ prolapse, uncomplicated urinary stones, and UTIs. Many urological conditions are suitable for telehealth, but more studies are needed on other highly prevalent urological malignant and benign conditions. Likely, the COVID-19 pandemic will give a significant boost to the use of telemedicine. More robust data on long-term efficacy, safety, and health economics are necessary. PATIENT SUMMARY: The diffusion of coronavirus disease 2019 (COVID-19) infections has recently increased the interest in telehealth, which is the adoption of telecommunication to deliver any health care activity. The available literature indicates that telemedicine has been adopted successfully in selected patients with several common clinical urological conditions, including prostate cancer, uncomplicated urinary stones, uncomplicated urinary infections, urinary incontinence, or pelvic organ prolapse. Likely, the COVID-19 pandemic will give a significant boost to the use of telemedicine, but more robust data on long-term efficacy, safety, and costs are necessary.
引用
- Novara G, Checcucci E, Crestani A, et al. Telehealth in Urology: A Systematic Review of the Literature. How Much Can Telemedicine Be Useful During and After the COVID-19 Pandemic? Eur Urol. 2020. PMID: 32616405. doi:10.1016/j.eururo.2020.06.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。